Wel-Bloom Biotech Launches Wel-ROS6. Black Crystal Roselle Sparks a Surge in High-Concentration Anthocyanins
Wel-Bloom Biotech and the LEARN EATiNG nutrition team host a high-profile seminar. (Image/Wel-Bloom)
In recent years, the health supplement market has seen rapid growth, accompanied by a shift in consumer priorities. Today's consumers increasingly believe that 'choosing the right ingredients matters more than simply taking more,' a mindset that is driving innovation in ingredient formulation. According to the 2024 Top 30 Dietary Trends Report, there is growing interest in the synergistic effects of ingredient combinations. For instance, pairing anthocyanins with fish oil offers comprehensive support for overall health, while combining them with collagen enhances beauty and skin wellness.
The Black Crystal Roselle, grown locally in Taiwan, contains naturally high levels of anthocyanins and has recently drawn growing interest in the health supplement field for its promising nutritional potential.
As one of the keynote speakers, Wel-Bloom Biotech introduced Wel-ROS6®—a proprietary botanical ingredient derived from Black Crystal Roselle. Developed using triple-patented technology, it is cultivated through natural farming methods and smallholder contract farming to ensure consistent quality and traceability. Laboratory data shows that Wel-ROS6® contains 17.7 times more total anthocyanins than standard commercial roselle. Additionally, total phenolic acids and flavonoids are elevated by 1.9 times and 1.3 times, respectively—highlighting its rich phytochemical profile and high functional value. (See Note 1)
The event also featured the Food Industry Research and Development Institute's newly proposed 'Food Value Equation":
Value = (Sensory Perception × Functional Technology × User Experience) × Amplification Multiplier.
This formula highlights the importance of balancing sensory appeal, technological innovation, and user experience—emphasizing that all three elements are essential to creating meaningful value in food products.
To meet growing consumer demands for convenience and palatability in health supplements, product development is increasingly focused on factors such as absorption efficiency, flavor optimization, and sustainable sourcing. The rise of 'tasty' health products reflects a major trend in preventive wellness—perfectly aligned with today's mindset of 'eating less, supplementing smarter.' Through its one-stop CDMO (Contract Development and Manufacturing Organization) services, Taiwan's local agriculture can now be transformed from raw materials into globally market-ready products that seamlessly integrate into everyday life.
Wel-ROS6®, backed by the support of over 300 health professionals, will be featured alongside other cutting-edge botanical ingredients at the 2025 BIO Asia–Taiwan Exhibition and Vitafoods Asia.
We warmly invite you to visit our booth and explore partnership opportunities with Wel-Bloom Biotech to co-create the next generation of best-selling health supplements.
Note 1:
Testing commissioned to the Food Industry Research and Development Institute:
Independent testing by the Forecast Research Lab:
Hashtag: #Welbloom #Wel-ROS6 #BlackCrystalRoselle
https://www.welbloom.com
The issuer is solely responsible for the content of this announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
12 minutes ago
- Miami Herald
LHH Joins the Recruitment Process Outsourcing Association to Advance the Evolution of RPO and Workforce Transformation
By joining the RPOA community of leaders, LHH is taking a leading and active role in shaping the future of RPO and establishing the practice as a strategic engine for organizational agility. NEW YORK CITY, NY / ACCESS Newswire / July 23, 2025 / LHH, a global integrated professional talent solutions provider and global business unit of the Adecco Group, today announced its Gold Membership with the Recruitment Process Outsourcing Association (RPOA). This move underscores LHH's commitment to advancing the RPO industry and marks a significant step in LHH's strategic expansion within the RPO sector, with its full offering centralized by The Adecco Group under LHH earlier this year. "Now that our RPO offering is fully integrated as LHH RPO, our partnership with RPOA is critical to ensure we are actively guiding the strategic evolution and new standard of RPO globally," shared Serge Shine, Global Head of LHH RPO. "LHH is the only provider that combines flexible RPO solutions with development and career transition services, helping organizations solve talent challenges holistically. We help organizations think bigger than just filling jobs. By connecting hiring to their larger talent priorities, we make every recruitment decision count. This comprehensive approach empowers our clients to hire smarter and pivot faster." "That's not the only thing that sets LHH RPO apart." Adds Alex Ridder, LHH RPO Head of Client Partnerships: "Talent acquisition isn't happening in isolation anymore, that's why we designed LHH's RPO offering to be highly adaptable. Whether it's scaling recruitment quickly in competitive markets, integrating new hiring tech without disrupting teams, or building talent pipelines for hard-to-fill roles, we help people make work meaningful while helping to tackle the tough challenges together. Our approach combines innovation and human centricity, with exceptional care, to deliver results that matter." With 400+ experts across five continents, LHH RPO works with clients across various industries to develop and optimize their RPO strategies through a comprehensive and flexible suite of RPO solutions, backed by global reach and local knowledge, to help drive cost efficiency and transform organizations across the entire talent lifecycle. Earlier this year, LHH RPO was named a 'Major Contender' in Everest Group's 2025 PEAK Matrix® for Global RPO Services, a milestone moment and a reflection of the impact LHH brings in rethinking talent solutions. "LHH joining the RPOA network supports our mission of fostering a collaborative community where RPO leaders can gather and share knowledge, transforming the future of the workforce collectively," said Lamees Abourahma, RPOA CEO. "LHH RPO provides value to our members addressing the challenges and needs of the RPO ecosystem with unique perspectives." She added, "We're thrilled to recognize and support LHH's RPO integration and market expansion and look forward to welcoming their experts to engage, learn and contribute to the evolution of the RPO industry. This is what the RPOA is all about, empowering leaders and advancing the profession." For more information on LHH RPO's offerings, visit LHH's Guide to Recruitment Process Outsourcing or contact LHH RPO. ### About LHH LHH empowers professionals and organizations to achieve bold ambitions and secure lasting impact through unique advisory services and professional talent solutions. LHH's full suite of offerings connects solutions that are traditionally siloed, making LHH a single talent partner for organizations. In a rapidly evolving landscape with complex challenges, we create value across the entire professional talent journey. From hiring great people, developing skills and nurturing leaders, to advancing individuals to the next stage of their careers, LHH makes talent a competitive edge. We believe the future of work lies at the intersection of exceptional human care and innovation. Powered by science, technology, and proprietary data analytics, LHH's approach is crafted to align with business strategies and cultures, delivering powerful, sustainable, and measurable impact. LHH has a team of over 12,000 professionals, across 60+ countries, and more than 50 years of experience. As part of the Adecco Group, we bring together global excellence, local knowledge and centralized coordination for thousands of companies and millions of people worldwide. Recruitment. Development. Career A beautiful working world. To learn more about LHH, visit: About RPOA The Recruitment Process Outsourcing Association (RPOA) is a member-driven, mission-driven organization committed to advancing, elevating, and promoting recruitment process outsourcing as a strategic talent solution. We strive to nurture a collaborative community, create thought leadership, and educate the marketplace about recruitment process outsourcing. Learn more at Media ContactsLHH Public RelationsPR@ RPOALamees Abourahma, CEOlamees@ The Adecco Group's RPO business was consolidated under LHH in January 2025. SOURCE: LHH
Business Wire
12 minutes ago
- Business Wire
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 Share Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, August 6, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows: Date: Wednesday, August 6 Time: 4:30 p.m. ET (1:30 p.m. PT) Toll-free dial-in number: +1 888 596 4144 Conference ID: 8584242 Webcast link: Niagen Bioscience Second Quarter 2025 Earnings Conference Call The conference call will be broadcast live and available for replay via the investor relations section of the Company's website at The replay of the conference call will be available from 7:30 p.m. ET on Wednesday, August 6, 2025, to 11:59 p.m. ET on Wednesday, August 13. The replay dial-in information is as follows: Toll-free replay number: +1 800 770 2030 Replay ID: 8584242 For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States † (available at and Niagen Plus ™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).
Business Wire
42 minutes ago
- Business Wire
Hyperfine Begins Commercial Launch of Optive AI™ Software, Bringing Substantially Improved Image Quality to the Installed Base of Swoop® Systems
GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the commercial launch of the Optive AI™ software for existing Swoop® system customers. Optive AI™ software, which also powers the transformative image quality of the next-generation Swoop® system, is now commercially available to customers in the U.S. With over 650 scans under our belt on the previous software, with just a single scan in critical care today after installing Optive AI™ software on the Swoop® system, the difference is crystal clear. Share Optive AI™ software enhances each stage of the imaging process—from noise cancellation and image acquisition to reconstruction and post-processing. The result is brain images with greater clarity, uniformity, and sharper anatomical detail. The FDA cleared Optive AI™ software in late May 2025, and the software is also available for commercial use in Canada, Australia, and New Zealand, with additional international approvals expected later this year. Hyperfine has now begun rolling out the new software to hospitals and outpatient neurology offices in the U.S. with plans to bring this imaging software to all current customers in the coming weeks. Jennifer Villa Frabizzio, MD, Chief of Neuroradiology, Jefferson Abington Hospital, noted, 'With over 650 scans under our belt on the previous software, with just a single scan in critical care today after installing Optive AI™ software on the Swoop® system, the difference is crystal clear. FLAIR images, especially, show markedly improved resolution and are 40 seconds faster. Kudos to Hyperfine engineers for this large leap.' Chetan Shah, MD, Chair, Pediatric Radiology, Wolfson Children's Hospital, noted, 'This upgrade is a true game changer for MRI technology—an overnight leap in image quality that's rarely seen. Portable MRI can now extend beyond the ICU to serve ER patients and outpatients—a breakthrough in every sense.' Optive AI™ software is fully compatible with first-generation Swoop® systems and requires no hardware modifications, enabling current users to immediately benefit from next-generation image quality. The new software supports a wide range of patient populations, as well as various clinical use cases in emergency, intensive care, and neurology office settings. 'We're thrilled to bring the power of Optive AI™ software to our current customers,' said Maria Sainz, President and CEO of Hyperfine. 'This is more than a software update—it's a milestone that reflects our commitment to sustained innovation, improved clinical performance, and driving the adoption of portable brain MRI across multiple sites of care. We are incredibly pleased with the feedback from the initial cases of patients scanned with the Optive AI™ software and look forward to broadening clinical utility with this high level of image quality for patients in different care settings inside and outside of the hospital.' For more information about the Swoop® system and Optive AI™ software, please visit About the Swoop® Portable MRI Systems The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
